Last reviewed 2026-04-19 · How we verify

aQII-11 Investigational

Seqirus · Phase 2 active Small molecule

aQII-11 Investigational is a Small molecule drug developed by Seqirus. It is currently in Phase 2 development.

At a glance

Generic name	aQII-11 Investigational
Sponsor	Seqirus
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

aQII-11 Investigational CI brief — competitive landscape report
aQII-11 Investigational updates RSS · CI watch RSS
Seqirus portfolio CI

Frequently asked questions about aQII-11 Investigational

What is aQII-11 Investigational?

aQII-11 Investigational is a Small molecule drug developed by Seqirus.

Who makes aQII-11 Investigational?

aQII-11 Investigational is developed by Seqirus (see full Seqirus pipeline at /company/seqirus).

What development phase is aQII-11 Investigational in?

aQII-11 Investigational is in Phase 2.

Manufacturer: Seqirus — full pipeline
Compare: aQII-11 Investigational vs similar drugs
Pricing: aQII-11 Investigational cost, discount & access